Massachusetts General Hospital
Corporate & Foundation Relations
Office of Development

PRIVATE FUNDING OPPORTUNITIES: FEB 24, 2017

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

*Please note that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submission of the award. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.*

1. Research Grant, Action for A-T

Action for A-T would like to invite medical research applications for research into ataxia telangiectasia. Applications are invited for high quality research projects that have the potential to lead to treatments and cures for the condition.

While UK based projects will be prioritised for funding, overseas applications are also actively encouraged.

Award Amount: £100,000 GBP paid over 3 years
Indirect Costs: None
Proposal Deadline: Apr 3, 2017
Website: http://actionforat.org/research/apply-for-a-research-grant/

2. Investigator's Award in Clinical Translation of Gene Therapy for Cancer: Investigator's Award in Clinical Translation of Cell and Gene Therapy for Cancer, Alliance for Cancer Gene Therapy (ACGT)

ACGT funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. To this end, ACGT offers awards to support research in clinical translation of cell and gene therapy for cancer.

ACGT RESEARCH OBJECTIVES

A number of cell and gene therapy approaches for cancer have been shown to be efficacious and safe in laboratory animal models in the recent years, but their translation into clinical trials has been hindered by a lack of resources. Recognizing this critical need, ACGT is accepting

grant applications to produce and release-testing of the clinical trial agents under cGMP, conduct the necessary pre-clinical pharmacological and toxicological studies in appropriate animal models, and/or conducting the clinical translational trials in patients in support of an Investigative New Drug (IND) application to the FDA. While the unambiguous demonstration of PRECLINICAL TREATMENT EFFICACY DATA IN TUMOR-BEARING ANIMALS in cancer treatment by cell and gene therapy is a pre-requisite, entering into the clinical trial during the funding period is also a requirement. Applications that do not include this specific aim will be deemed unresponsive to the RFA.

Award Amount: $500,000 paid over 2-3 years
Indirect Costs: 10%
LOI Deadline: Mar 21, 2017
Website: http://www.acgtfoundation.org/grants-and-research/research-grants/

3. Effect of Augmentation Therapy on COPD Exacerbations in Alpha-1 Antitrypsin Deficiency, Alpha-1 Foundation (A1F) New

Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic (inherited) condition - it is passed from parents to their children through their genes. Alpha-1 may result in serious lung disease in adults and/or liver disease at any age.

The purpose of this RFA is to assess the effect of intravenous augmentation therapy compared to placebo on acute pulmonary exacerbations (frequency and/or severity and/or time to first exacerbation) in patients with severe alpha-1 antitrypsin deficiency (serum alpha-1 antitrypsin level <50mg/dl when clinically stable).

Given the uncertainty about the relationship between augmentation therapy and acute pulmonary exacerbations in alpha-1 antitrypsin deficiency-associated COPD, there is a need for a prospective placebo-controlled study designed to assess the effect of augmentation therapy on exacerbations. A definitive answer to this question is of considerable importance to investigators in view of the demonstrated impact of exacerbations on health status and the need to improve the patients' health-related quality of life. The definition of exacerbations has varied in previous investigations and may in part explain the inconsistent results. It is therefore important to clearly articulate the criteria used to define the presence, severity and duration of pulmonary exacerbations in future studies.

Award Amount: $500,000 paid over 2 years
Indirect Costs: None
Application Deadline: May 8, 2017
Website: https://www.alpha1.org/Investigators/Grants/Grant-Opportunities

4. International Research Grant Program: Alzheimer's Association Research Fellowship to Promote Diversity (AARF-D) Program, Alzheimer's Association (ALZ)
The Alzheimer's Association Research Grant aims to increase the number of scientists from underrepresented groups at academic institutions in Alzheimer's or related dementias research. The AARG-D aims to fund investigators who are less than 10 years past their doctoral or post residency (MD or DO) or investigators that are new to Alzheimer's and related dementia field of research even if past the 10 years.

The objective of this award is to increase the number of highly trained investigators from diverse backgrounds whose basic, clinical and social/behavioral research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to Alzheimer's and related dementias in general and in health disparities populations. The Alzheimer's Association recognizes the need to increase the number of scientists from underrepresented groups participating in biomedical and behavioral research. The Association anticipates that by providing these research opportunities, the number of scientists from underrepresented groups entering and remaining in biomedical research careers in Alzheimer's disease will increase.

The purpose of this program is to provide new scientists from underrepresented groups with funding that will allow them to develop preliminary or pilot data, to test procedures, and to develop hypotheses. The intent is to support early-career development that will lay the groundwork for future research grant applications to the National Institutes of Health, National Science Foundation and other funding agencies and groups, including future proposals to the Alzheimer's Association.

Award Amount: $175,000 paid over 2-3 years
Indirect Costs: 10%
LOI Deadline: Mar 1, 2017
Website: http://www.alz.org/research/alzheimers_grants/types_of_grants.asp

5. ASRM Research Grants (ASRM and SREI Research Grant Programs), American Society for Reproductive Medicine (ASRM)
The priorities of the ASRM Research Grant Program are to (1) facilitate the research endeavors of new investigators, (2) provide bridge (i.e., between grant funding periods) funds for projects that are of benefit to other members of the Society, and (3) foster the development of innovative research.

Award Amount: Up to $50,000 for 1-2 years
Indirect Costs: 10%
Application Deadline: Mar 13, 2017
Website: http://www.asrm.org/ASRM_Research_Grants/

6. PNH Research Grant, Aplastic Anemia & MDS International Foundation, Inc. (AA&MDSIF)

AA&MDSIF is pleased to help researchers dedicated to the study of bone marrow failure advance the understanding and treatment of aplastic anemia, myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). For more than twenty five years, AA&MDSIF has provided financial support to research that leads to new insights into the causes of the bone marrow failure and that leads to the development of new therapeutic approaches.

With funding provided by the Patricia and Vincent Geczik Legacy Gift to Fund PNH Research, AA&MDSIF is requesting proposals for research grant projects on the following topics:

- Anti-complement therapies and/or immune regulation: Increased understanding of C3 inhibitors
- Role of bone marrow failure in the selection of PNH clones of hematopoietic stem cells
- Cause of the expansion of the PNH clone to clinically significant levels
- Genetic components of PNH
- Increased understanding of thrombosis within PNH, including mechanisms, detection and diagnosis, and treatment
- Health outcomes of extended use of eculizimab
- Reasons for continued clinical manifestations despite or because of the response to eculizimab
- Advances in drug delivery mechanisms
- More effective dosing levels and combination therapies

In addition, the following criteria will be considered by reviewers:

- The likelihood that the goals of the proposal are attainable with the funding from AA&MDSIF;
- The project is independent research and not part of a large, multi-funded study;
- The translational nature of the research and whether the findings can be rapidly applied to benefit patients;
- For New Investigators, the likelihood that the project will contribute toward the professional development of the researcher.

Award Amount: Up to $250,000 paid over 1-2 years
Indirect Costs: 10%
Application Deadline: Feb 28, 2017
Website: http://www.aamds.org/professionals/fund-your-research

7. ASF, Macquarie, Pedersen Family, KFOC Alport Syndrome Research Funding Program, Kidney Foundation of Canada (KFOC)

The Alport Syndrome Foundation, Inc. (ASF), Pedersen Family and the Kidney Foundation of Canada (KFOC) are pleased to announce the availability of funding for basic science and clinical

research on the natural history, biochemical basis, and treatment of Alport Syndrome. There are no geographical limitations of this funding.

The objective of this research funding program is to advance the knowledge of, develop effective treatment protocols for, and discover a cure for Alport Syndrome Foundation.

Funding will be provided for basic science or clinical research on Alport Syndrome. These funds may be used as seed funding for the testing of initial hypotheses and the collection of preliminary data leading to successful long-term funding by the National Institutes of Health (NIH), the Canadian Institutes of Health Research (CIHR), or other major funding institutions around the world.

Award Amount: Up to $100,000 USD paid over 1-2 years
Indirect Costs: None
Application Deadline: Mar 20, 2017
Website: http://www.kidney.ca/other-funding-opportunities/alport-syndrome

8. Center for Regulatory Excellence (CRE), National Council of State Boards of Nursing (NCSBN)
The CRE grant program provides funding for scientific research projects that advance the science of nursing policy and regulation and build regulatory expertise worldwide.

Research Priorities:

- National and International Regulatory Issues
- Patient Safety
- Practice (LPN/VN, RN and APRN)
- Nursing Education
- Continued Competence
- Nurse Mobility
- Substance Use

Award Amount: Up to $300,000 paid over 1-2 years
Indirect Costs: None
Proposal Deadline: Apr 7, 2017
Website: https://www.ncsbn.org/center-for-regulatory-excellence.htm

9. Independent Grants for Learning & Change (IGL&C): Track 2 - Call for Grant Applications (CGA) - Knowledge Gaps for Pharmacists in CDK 4/6 Therapies for Advanced or Metastatic Breast Cancer Treatment, Pfizer, Inc.
The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest

through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

Clinical Area: Advanced or Metastatic Breast Cancer: CDK 4/6 Inhibition
Specific Area of Interest for this CGA: It is our intent to support continuing professional development programs for pharmacists and pharmacy managers involved in the treatment of patients with advanced or metastatic breast cancer.

Pharmacists are often called upon to advise other members of the care team on specifics of treatments, interactions, dosing, and side effects. They frequently need to answer patient questions and provide support throughout the breast cancer treatment journey. Proposed programs should increase the awareness and understanding of the emerging clinical and real world data for the use of CDK 4/6 inhibitors in treating patients with advanced or metastatic breast cancer.

Examples of topics that could be addressed are:

- Dosing and dose adjustments
- Drug interactions
- Adverse events
- Importance of monitoring
- Lab value interpretation based on guidelines

All activity types will be considered through this CGA, including live events, satellite symposia, workshops, online courses, print materials, and other enduring materials including published proceedings. Efforts should be made to encourage interaction, incorporate patient case discussions, and provide opportunities to extend and reinforce learning opportunities beyond the live setting.

Award Amount: $500,000 paid over 2 years
Indirect Costs: 28%
Application Deadline: Mar 22, 2017
Website: http://www.pfizer.com/responsibility/grants_contributions/grants_process

10. Advancing Science through Pfizer: Investigator Research Exchange (ASPIRE) Gene Therapy for Hemophilia Research Awards Program, Pfizer, Inc.
The 2017 ASPIRE Gene Therapy in Hemophilia Research Awards Program is a competitive grants program that reflects the commitment of Pfizer Hemophilia Rare Disease group to support ongoing basic science and clinical investigation in gene therapy for hemophilia.

Ongoing basic science research and clinical research are critical to deepen understanding of disease mechanisms and to ensure advancement of management strategies for hemophilia and related comorbidities. In an era of increased competition for research funding, the 2017 ASPIRE Gene Therapy in Hemophilia Research Awards Program is designed to support laboratory and clinical research in pathogenesis, complications, management, and clinical outcomes of gene therapy for hemophilia.

Mission
To support research through a competitive grants program that advances medical knowledge in the area of Gene Therapy for Hemophilia. The 2017 program will focus on Hemophilia B.

Areas of Research Focus
1. Patients with Mild Hemophilia B
- Natural history of disease
- Arthropathy: presence, development, clinical burden & Joint damage
- Quality of Life/Work analysis
- Clinical profile & healthcare utilization
- Comorbidities: prevalence, severity, management
- Cost of Care, including non-hemophilia related healthcare utilization

2. Basic science of Adeno-associated virus 8 (AAV8)
- Basic science, tropism, transduction efficiency & tolerability
- AAV antibody titer assessment, reduction, tolerance
- Role of immunosuppression in managing transaminitis & expression levels

Applicants/Investigators are expected to:
- Design studies and generate data to address at least one of the Research Areas of interest
- Provide a Publication Plan describing submission of abstracts to (a) congress(es) or submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines.
- Complete the study within 24-30 months from the time that the grant is awarded

No other government, non-governmental, or industry-sponsored projects may cover the same scope of work as the grant application to the ASPIRE Research Awards Program. However, an ASPIRE Research Award may be related to other funding from foundations or government agencies, as long as there is no direct overlap. In the application, it is the responsibility of the applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding.

Award Amount: Up to $250,000 paid over 1-2 years
Indirect Costs: 28%
Application Deadline: Mar 31, 2017
Website: http://www.aspireresearch.org/genetherapyforhemophilia/index.html

11. Mentoring and Wellness RFP, Physicians Foundation New

The Physicians Foundation is seeking to support the development of an innovative, evidence-based mentorship model for physicians that encourages professional fulfillment and reduces burnout. Funding is available to support research that elevates mentoring as a vehicle to increase professional fulfillment and decrease the incidence or severity of physician burnout.

Background/Overview

Mentoring reduces burnout and increases professional fulfillment by enhancing professional relationships and providing opportunities for learning from peers. There are many ways in which mentoring can take place. The more common vertical structure has mid- or late- career physicians model the virtues and skills of their profession for early-career practicing physician or those in medical school or post-graduate training. There is also a significant opportunity for horizontal, or peer to peer, mentoring between practicing physicians. Physicians can all learn and be inspired by sharing experiences that increase connectedness, meaning, and purpose in professional endeavors. The Physicians Foundation seeks to learn more about the effects of both peer-to-peer and traditional vertical mentoring with particular interest in research leading to improved knowledge of the effects of either mentoring approach on professional fulfillment and burnout.

Practicing physicians are experiencing a number of challenges - a loss of connections with other doctors, decreased professional stature, increasing regulatory, payer, and operational demands, and a complexity that emphasizes metrics in place of the art of medicine. There is a greater sense of pessimism about the state of the profession, which has drained the joy out of practice for many physicians. This sentiment has been compounded by the loss of professional peer camaraderie that was once inspiring and validating. At the same time, these physicians are teaching, supervising, and working with students, residents, and physicians in their early years of practice and imparting a sense of futility and negativity. During a time when the students and residents are vulnerable to criticism, the negative feedback about the profession and health care from those who teach and mentor them can be detrimental. It can contribute to a disillusionment with their experience, leading to early and severe burnout that is manifested in the high frequency of depression and suicide in the student and resident population. This disillusionment early on sets up future physicians for an unfulfilling career and can be a great disservice to society and the profession.

Purpose
Mentoring should be considered an important professional exercise and should be a part of lifelong learning. The proposed project should consider some or all of the following aspects of mentorship models, including:

- Curriculum that has adaptations for stage, age, specialty, and ongoing engagement
- Methods for matching mentors and mentees
- Screening tools for identifying physicians at risk for significant mental health issues
- Measuring impact and outcomes of mentorship models
- Mentoring as a Maintenance of Certification (MOC) project

Efforts to address concerns around physicians' professional fulfillment often seek to address the growing number of administrative burdens and regulations as well as offering leadership programs to elevate the physicians' voice. In addition to the work that the Foundation supports in those areas, it would like to address the other social and emotional burdens that physicians face through the research outlined in this RFP. Specifically, the Physicians Foundation seeks to support research that addresses one or more of the following questions:

- Fulfillment: Can mentoring contribute to an improvement in professional fulfillment and decrease the rate of burnout?
- Rejuvenation: Can mentoring programs be developed that help doctors re-center on the ideals and attributes of being a physician and connect them with peers and young physicians?
- Restoration: Can mentoring be a helpful way to heal and sustain those who have experienced burnout and help them reground their professional identity?
- Connection: What are the essential attributes, skills, or processes of mentorship experiences that enhance professional fulfillment and prevent burnout?

Award Amount: $100,000 paid over 2 years
Indirect Costs: 15%
Proposal Deadline: Mar 2, 2017
Website: http://www.physiciansfoundation.org/healthcare-grants/current-rfps/new-physician-leadership-rfp/

12. Research Grants, Scoliosis Research Society (SRS)
The purpose of the SRS is to foster the optimal care of all patients with spinal deformities. The SRS has maintained a commitment to research and education in the field of spinal deformities.

SRS offers five levels of grants:

- Small Exploratory Grant
- This grant is designed specifically for new investigators who have a preliminary concept that they would like to develop into a research project. The grant application does not require pilot data. It should, however, be able to generate pilot data that could be used when applying for a larger grant.

- New Investigator Grant
- This grant is specifically targeted towards new investigators. Preliminary data is suggested although not absolutely required.
    - Standard Investigator Grant
- These grant applications may be in any area of spinal deformity research, although an additional funding source for grants focusing on the etiology of scoliosis is available in conjunction with the Cotrel Foundation. Preliminary data is generally required.
    - Alf Nachemson Evidence Based Medicine Grant
- The award is given to studies that aim to provide the best available evidence by which to improve our knowledge and practice in the care of patients with spinal deformities.
    - Continuation or Extension Grant
- Continuation or extension of an on-going project, which has been previously funded by the Scoliosis Research Society will be considered. These additional grant requests require a report on the progress of the work completed to date. In addition, justification for the additional funding and/or time necessary to complete the project is required.

Additionally, Risk Stratification Grants can be applied for in any of the above topics.

The Research Grant Committee feels the following topics are important areas for research. This list is not all-inclusive and should not deter other areas of spinal pathology research.

1. Evidence Based Medicine
2. Idiopathic scoliosis
3. Etiology
4. Non-op and operative treatment
5. 3D deformity of the spine and thorax
6. Adult deformity
7. Treatment and outcomes
8. Osteoporosis
9. Early onset scoliosis treatment
10. Sagittal imbalance
11. Congenital scoliosis
12. Neuromuscular spinal deformity
13. Deformity and reconstruction arising from spine and sacral tumor treatment
14. Thoracic insufficiency children associated with spinal deformity
15. Pulmonary outcome sequeallae following common natural history of spine deformity and treatment history.
16. Risk Stratification

Award Amount: $10,000-$50,000
Indirect Costs: None
Application Deadline: Apr 1, 2017
Website: http://www.srs.org/professionals/research-and-journal/research-grants